Cannabis Enhances Bipolar Patients' Neurocognitive Performance

According to a study published online in the journal Psychiatry Research, individuals with bipolar disorder who used cannabis showed higher neurocognitive performance than patients who did not use cannabis...

Bufexamac 1353882-38-8

Crowdsourcing Cures

NIH initiative aims to partner academics with pharmaceutical companies to revive failed drug candidates

Click here Cabazitaxel Cabazitaxel 183133-96-2

Shear-Activated Clot-Busting Drug

Biophysical strategy tears apart drug-carrying nanoparticle clusters to more efficiently clear blocked blood vessels

Bufexamac 2438-72-4 Bufexamac 1353882-38-8 More information

Education Lengthens Life Expectancy

According to a new study published in the August issue of the journal Health Affairs, people in the United States with less than a high school education have life expectancies comparable to adults in the 1950s and 1960s. S...

More information Learn more Click here

More Than Just A Smiley Face

Researchers struggle to find practical applications for nanoscale patterning technique

More information Learn more Click here

Dihydrofuro pyrimidines as akt protein kinase inhibitors

The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula (I): Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer....

Cabazitaxel Cabazitaxel 183133-96-2 Cabazitaxel 890654-44-1

Effects of intra-articular injections of bufexamac suspension in healthy horses.

Related Articles

Effects of intra-articular injections of bufexamac suspension in healthy horses.

Am J Vet Res. 2001 Oct;62(10):1629-35

Authors: Suominen MM, Tulamo RM, Anttila MO, Sankari SM, Kir�ly K, Lapvetel�inen T, Helminen HJ

Abstract
OBJECTIVE: To evaluate the effects of intra-articular (IA) injections of bufexamac in horses, focusing particularly on the effects of bufexamac on articular cartilage.
ANIMALS: 20 Standardbreds.
PROCEDURE: Horses were randomly allocated into 4 groups consisting of 5 horses each, and 20, 60, or 100 mg of bufexamac or 1 ml of sterile saline (0.9% NaCl) solution (control) was injected into 1 intercarpal joint at weekly intervals for 6 treatments (days 0, 7, 14, 21, 28, and 35). Clinical signs and results of hematologic, serum biochemical, and synovial fluid (SF) analyses and radiography were used to evaluate treatment effects. On day 49, all horses were euthanatized; gross necropsy and histologic examinations of internal organs and articular tissues were performed. Glycosaminoglycan concentration of the articular cartilage was evaluated in safranin O-stained sections by use of a semiquantitative microspectrophotometric method.
RESULTS: No systemic signs were observed. Temporary mild to moderate heat and effusion were the only clinical signs observed in a number of joints after IA injections and more often only in the 100 mg group, compared with controls. The 100 mg dose resulted in significant increases in SF WBC counts, with relative neutrophilia and SF total protein concentration 24 hours after injection (day 1). No lesions suggestive of toxic effects were detected at necropsy or on histologic examination. No changes in articular cartilage glycosaminoglycan concentration were detected.
CONCLUSIONS AND CLINICAL RELEVANCE: Six injections of 20, 60, or 100 mg of bufexamac at weekly intervals did not cause any untoward systemic or local effects. These data suggest that bufexamac is a safe nonsteroidal anti-inflammatory drug for IA administration in horses.

PMID: 11592331 [PubMed - indexed for MEDLINE]

Cabazitaxel Cabazitaxel 183133-96-2 Cabazitaxel 890654-44-1